PedAM
Pediatric Disease Annotations & Medicines
| Disease | spasticity |
| Phenotype | C0026769|multiple sclerosis |
| Sentences | 52 |
| PubMedID- 21456949 | Thc and cbd oromucosal spray (sativex(r)) in the management of spasticity associated with multiple sclerosis. |
| PubMedID- 26409407 | Anodal transcranial direct current stimulation of motor cortex does not ameliorate spasticity in multiple sclerosis. |
| PubMedID- 24305054 | Baclofen, a selective gabab agonist, is used clinically to treat muscle spasticity associated with multiple sclerosis, cerebral palsy, and spinal cord injury1–3. |
| PubMedID- 22721367 | [pharmacological treatment of spasticity in multiple sclerosis]. |
| PubMedID- 21476822 | Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in spain: the '5e' study. |
| PubMedID- 22726074 | Cannabis derivatives [tetrahydrocannabinol (thc) and cannabidiol (cbd)] are available as an oromucosal spray (sativex((r))), indicated as add-on treatment, for symptom improvement in patients with moderate to severe spasticity because of multiple sclerosis (ms). |
| PubMedID- 22660477 | Baclofen, a specific gabab receptor agonist, is used clinically to treat muscle spasticity in patients with multiple sclerosis, brain and spinal cord injuries2,3. |
| PubMedID- 25531685 | Mobility improvement with spasticity in multiple sclerosis in europe: the move 1 eu study. |
| PubMedID- 23046749 | Both components have a distinct pharmacology, and together have been shown to relieve spasticity in people with multiple sclerosis [9-11]. |
| PubMedID- 20234785 | Cannabinoids such as cannabis-based medicinal extracts (cbmes) are increasingly being used in the treatment of spasticity associated with multiple sclerosis (ms). |
| PubMedID- 22739983 | Cbd exerts anti-inflammatory, antioxidant and neuroprotective effects,1 and it has been approved for the treatment of inflammation, pain and spasticity associated with multiple sclerosis (ms).2 studies in an animal model of eae have shown that cbd ameliorates the severity of the disease by attenuating neuroinflammation and axonal damage.3 oligodendrocyte progenitor cells (opcs) are relatively quiescent cells derived from precursors of the perinatal cns that make up around 5–8% of the glial cell population in the adult; in the injured cns, they can divide and are thought to differentiate to new myelinating oligodendroytes that replace those that have been lost in demyelinating areas.4 opcs are highly vulnerable to inflammation and oxidative stress as they have a high metabolic rate, high intracellular iron, and low concentrations of the antioxidative glutathione; they also express an arsenal of molecules rendering them susceptible to inflammatory cytokines or high calcium levels among others.5 it is known that inflammation contributes to oligodendroglial damage in demyelinating diseases such as ms.6 synthetic cannabinoids such as win 55212-2 and hu211 can protect oligodendrocyte progenitors cells (opcs) from the apoptosis induced by the withdrawal of trophic support,7 although their utility is limited due to their unwanted psychotropic effects. |
| PubMedID- 22536451 | Indeed this was part of the rationale behind the development of sativex®, a cannabinoid formulation containing a 1.07∶1 thc ∶ cbd dose, approved for use in various countries for the treatment of spasticity associated with multiple sclerosis. |
| PubMedID- 25121144 | Conventional drugs have only a limited impact on spasticity associated with multiple sclerosis and are rarely satisfactory. |
| PubMedID- 24883390 | The first study [11] concerned a population of patients with multiple sclerosis complicated by spasticity but did not provide any details concerning the spinal or cerebral site of multiple sclerosis. |
| PubMedID- 22573509 | Some of these pharmaceuticals, such as the mouth spray sativex, have recently been approved for the treatment of spasticity in multiple sclerosis, but they are not the first and others, such as marinol or cesamet for the treatment of vomiting and nausea, and anorexia-cachexia syndrome, had already been approved. |
| PubMedID- 21144973 | Background: cannabidiol, the most abundant nonpsychoactive constituent of cannabis sativa (marijuana) plant, exerts anti-inflammatory effects in various disease models and alleviates pain and spasticity associated with multiple sclerosis in humans. |
| PubMedID- 23642347 | The main therapeutic results were improvement on the gross motor function classification scale and in upper limb dexterity (cerebral palsy); improvement in social functioning and interaction; reductions in stress, anxiety, and loneliness (pervasive developmental disorders and mental disorders); and decreased spasticity with improved balance (multiple sclerosis, spinal cord injury, stroke). |
| PubMedID- 22878432 | During a 6-week randomised controlled trial, sativex had a clinically relevant effect on spasticity associated with multiple sclerosis (ms). |
| PubMedID- 22354705 | Activation of cannabinoid (cb) receptors decreases nociceptive transmission in acute, inflammatory and neuropathic pain states; however, although the use of cannabis derivatives has been recently accepted as a useful alternative for the treatment of spasticity and pain in patients with multiple sclerosis, the effects of cb receptor agonists in muscular pain have hardly been studied. |
| PubMedID- 25931667 | Patient-identified factors that influence spasticity in people with stroke and multiple sclerosis receiving botulinum toxin injection treatments. |
| PubMedID- 23373525 | The meaning of spasticity to people with multiple sclerosis: what can health professionals learn. |
| PubMedID- 24701201 | Hd of both h-reflex and sr amplitudes in response to previous stretch of the so muscle have been compared between neurologically intact and participants with spasticity arising from multiple sclerosis or spinal cord injury (nielsen et al., 1995; grey et al., 2008). |
| PubMedID- PMC4036658 | The results showed that cbm improved the symptoms of spasticity in multiple sclerosis and that delta9-thc plus cbd was better tolerated than delta9-thc as a single molecule [77]. |
| PubMedID- 20806080 | In addition, cbd has been approved for the treatment of inflammation, pain, and spasticity associated with multiple sclerosis in humans (reviewed in [52]). |
| PubMedID- 24081891 | [consensus document on spasticity in patients with multiple sclerosis. |
| PubMedID- 26166264 | Effect of sativex on spasticity-associated symptoms in patients with multiple sclerosis. |
| PubMedID- 21982341 | It is used for the symptomatic relief of spasticity associated with multiple sclerosis or with spinal cord injury or disease. |
| PubMedID- 26445705 | spasticity in multiple sclerosis and role of glatiramer acetate treatment. |
| PubMedID- 25158585 | Cannabinoid was licensed in 2012 for the treatment of spasticity associated with multiple sclerosis in finland. |
| PubMedID- 22615658 | Baclofen, a centrally acting skeletal muscle relaxant, is indicated in the long-term treatment of spasticity resulting from multiple sclerosis and spinal cord injuries. |
| PubMedID- 22133480 | spasticity improvement in patients with relapsing-remitting multiple sclerosis switching from interferon-beta to glatiramer acetate: the escala study. |
| PubMedID- 24292503 | Burden of disease in multiple sclerosis patients with spasticity in germany: mobility improvement study (move i). |
| PubMedID- 23297730 | Information regarding the epidemiology of spasticity in patients with multiple sclerosis (ms) in spain is limited. |
| PubMedID- 23543344 | Does giving segmental muscle vibration alter the response to botulinum toxin injections in the treatment of spasticity in people with multiple sclerosis. |
| PubMedID- 22409179 | Botulinum toxin, specifically toxin type a (bont-a) has been used since the 1970s to treat many different disorders, such as general spasticity resulting from stroke, multiple sclerosis or cerebral palsy, strabismus, hyperhidrosis or excessive sweating, pain, and it is effective in combating migraine and tension headaches. |
| PubMedID- 23011861 | [treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids]. |
| PubMedID- 19863647 | Effects of intermittent theta burst stimulation on spasticity in patients with multiple sclerosis. |
| PubMedID- 20558502 | Meta-analysis of the efficacy and safety of sativex (nabiximols), on spasticity in people with multiple sclerosis. |
| PubMedID- 20505376 | F-wave characteristics as surrogate markers of spasticity in patients with secondary progressive multiple sclerosis. |
| PubMedID- 24256407 | spasticity in patients with multiple sclerosis--clinical characteristics, treatment and quality of life. |
| PubMedID- 23582109 | Comparison of the effect of baclofen and transcutaneous electrical nerve stimulation for the treatment of spasticity in multiple sclerosis. |
| PubMedID- 22721362 | spasticity in multiple sclerosis]. |
| PubMedID- 22629287 | Most research using oral preparations has targeted neuropathic pain and spasticity associated with multiple sclerosis (ms). |
| PubMedID- 24699310 | Sativex((r)) is an oromucosal spray used to treat spasticity in multiple sclerosis sufferers in some european countries, the united kingdom, canada and new zealand. |
| PubMedID- 23072659 | Background: spasticity is common in patients with multiple sclerosis (ms) and is a major contributor to disability. |
| PubMedID- 23371380 | [importance and treatment of spasticity in multiple sclerosis : results of the move 1 study]. |
| PubMedID- 25649546 | (1995) demonstrated that decreased presynaptic inhibition played a role in spasticity in people with multiple sclerosis and spinal cord injury [21], in spasticity due to stroke, it seems not to be a systematic contributor [22, 24]. |
| PubMedID- 23108552 | These can be prescribed for the amelioration of chemotherapy-induced nausea and vomiting (cesamet and marinol), stimulation of appetite (marinol) and symptomatic relief of cancer pain and/or management of neuropathic pain and spasticity in adults with multiple sclerosis (sativex). |
| PubMedID- 25835097 | [a breakthrough for the treatment of spasticity in multiple sclerosis]. |
| PubMedID- 25623252 | The high cost of spasticity in multiple sclerosis to individuals and society. |
Page: 1 2